Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
Blood. 2024 May 23;143(21):2178-2189. doi: 10.1182/blood.2023023120.
Blood. 2024.
PMID: 38394665
Free article.
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I, Boer JM, van de Ven C, Reichert CEJ, Boeree A, Kruisinga B, de Groot-Kruseman HA, Escherich G, Sijs-Szabo A, Rijneveld AW, den Boer ML.
van Outersterp I, et al. Among authors: reichert cej.
Blood Adv. 2024 Apr 23;8(8):1835-1845. doi: 10.1182/bloodadvances.2023012162.
Blood Adv. 2024.
PMID: 38386975
Free PMC article.
Item in Clipboard
Cite
Cite